OBJECTIVE: The objective of this study is to assess clinical variables that may be associated with risk for opioid misuse in individuals with chronic pancreatitis. DESIGN: This study utilized a descriptive, quasi-experimental, cross sectional design. SETTING AND PATIENTS: Three hundred seven individuals with nonalcoholic chronic pancreatitis engaged in chronic opioid therapy for pain presented to an outpatient specialty clinic at an academic medical center. MEASURES: Participants completed the Current Opioid Misuse Measure (COMM), Brief Pain Inventory (BPI), Short Form (SF)-12 Quality of Life Measure, Center for Epidemiological Studies 10-item Depression Scale (CESD), and a single item asking about current alcohol use. Mean scores on the CESD, COMM, BPI, SF-12, and factors associated with opioid misuse measures from regression analyses were the outcome measures. RESULTS: Mean scores on the CESD, COMM, BPI pain-on-average item, and the SF-12 physical and psychological quality of life factors (t scores) were 11.2 (standard deviation [SD] = 6.7), 8.5 (SD = 7.3), 4.8 (SD = 2.8), 39.7 (SD = 7.0), and 45 (SD = 9.0), respectively. Descriptive analyses revealed that 55% of participants scored above the clinical cutoff for depression on the CESD, and 39% scored above the cutoff for opioid misuse concerns on the COMM. Regression analyses identified several factors associated with higher opioid misuse measure scores, including increased depressive symptoms from the CESD (β = 0.38, P < 0.0001), increased pain rating at the time of the office visit (β = 0.16, P = 0.03), impairment of psychological quality of life (β = -0.27, P = 0.001) and endorsement of alcohol use (β = 0.16, P = 0.03). These factors accounted for 37% of the variance in current opioid misuse scores. CONCLUSIONS: Depression, quality of life, pain intensity and alcohol use may be good candidate variables for prospective studies to determine clinical risk factors for opioid misuse among patients with pancreatitis. Wiley Periodicals, Inc.
OBJECTIVE: The objective of this study is to assess clinical variables that may be associated with risk for opioid misuse in individuals with chronic pancreatitis. DESIGN: This study utilized a descriptive, quasi-experimental, cross sectional design. SETTING AND PATIENTS: Three hundred seven individuals with nonalcoholic chronic pancreatitis engaged in chronic opioid therapy for pain presented to an outpatient specialty clinic at an academic medical center. MEASURES: Participants completed the Current Opioid Misuse Measure (COMM), Brief Pain Inventory (BPI), Short Form (SF)-12 Quality of Life Measure, Center for Epidemiological Studies 10-item Depression Scale (CESD), and a single item asking about current alcohol use. Mean scores on the CESD, COMM, BPI, SF-12, and factors associated with opioid misuse measures from regression analyses were the outcome measures. RESULTS: Mean scores on the CESD, COMM, BPI pain-on-average item, and the SF-12 physical and psychological quality of life factors (t scores) were 11.2 (standard deviation [SD] = 6.7), 8.5 (SD = 7.3), 4.8 (SD = 2.8), 39.7 (SD = 7.0), and 45 (SD = 9.0), respectively. Descriptive analyses revealed that 55% of participants scored above the clinical cutoff for depression on the CESD, and 39% scored above the cutoff for opioid misuse concerns on the COMM. Regression analyses identified several factors associated with higher opioid misuse measure scores, including increased depressive symptoms from the CESD (β = 0.38, P < 0.0001), increased pain rating at the time of the office visit (β = 0.16, P = 0.03), impairment of psychological quality of life (β = -0.27, P = 0.001) and endorsement of alcohol use (β = 0.16, P = 0.03). These factors accounted for 37% of the variance in current opioid misuse scores. CONCLUSIONS:Depression, quality of life, pain intensity and alcohol use may be good candidate variables for prospective studies to determine clinical risk factors for opioid misuse among patients with pancreatitis. Wiley Periodicals, Inc.
Authors: Alicia Grattan; Mark D Sullivan; Kathleen W Saunders; Cynthia I Campbell; Michael R Von Korff Journal: Ann Fam Med Date: 2012 Jul-Aug Impact factor: 5.166
Authors: Ellen C Meltzer; Denis Rybin; Richard Saitz; Jeffrey H Samet; Sonia L Schwartz; Stephen F Butler; Jane M Liebschutz Journal: Pain Date: 2010-12-21 Impact factor: 6.961
Authors: Markus Wehler; Ralf Nichterlein; Bernhard Fischer; Michael Farnbacher; Udo Reulbach; Eckhart Georg Hahn; Thomas Schneider Journal: Am J Gastroenterol Date: 2004-01 Impact factor: 10.864
Authors: San Keller; Carla M Bann; Sheri L Dodd; Jeff Schein; Tito R Mendoza; Charles S Cleeland Journal: Clin J Pain Date: 2004 Sep-Oct Impact factor: 3.442
Authors: Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski Journal: J Pain Date: 2009-02 Impact factor: 5.820
Authors: Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison Journal: Pain Date: 2007-05-09 Impact factor: 6.961
Authors: Salva N Balbale; Itishree Trivedi; Linda C O'Dwyer; Megan C McHugh; Charlesnika T Evans; Neil Jordan; Laurie A Keefer Journal: Dig Dis Sci Date: 2017-08-05 Impact factor: 3.199
Authors: Dan Werb; Ayden I Scheim; Ayorinde Soipe; Samantha Aeby; Indhu Rammohan; Benedikt Fischer; Scott E Hadland; Brandon D L Marshall Journal: Drug Alcohol Rev Date: 2022-04-18